Table 1 Characteristics of subjects according to the level of blood pressure variability (n = 144)

n

48

48

48

Age (years)

72.3 ± 9.1

70.8 ± 8.5

74.7 ± 8.7

0.101^a

Male

24 (50.0%)

21 (43.8%)

19 (39.6%)

0.586^b

Blood pressure measurements (times)

9.1 ± 3.1

9.5 ± 2.6

9.7 ± 2.8

0.569^a

Systolic blood pressure (mmHg)

130.2 ± 10.1

132.0 ± 12.2

131.5 ± 16.9

0.801^a

Diastolic blood pressure (mmHg)

72.1 ± 11.0

72.8 ± 11.8

71.2 ± 10.3

0.780^a

Pulse pressure (mmHg)

58.1 ± 12.3

59.2 ± 11.5

60.3 ± 15.4

0.728^a

Heart rate (beats/min)

73.8 ± 9.8

70.5 ± 6.8

72.3 ± 6.9

0.248^a

Antihypertensive medication

33 (68.8%)

38 (79.2%)

41 (85.4%)

0.140^b

  Calcium-channel blocker

27 (56.3%)

30 (62.5%)

34 (70.8%)

0.331^b

  Renin-angiotensin antagonist

20 (41.7%)

19 (39.6%)

24 (50.0%)

0.553^b

  β-blocker

6 (12.5%)

9 (18.8%)

3 (6.3%)

0.180^b

Fasting plasma glucose (mg/dL)

116.3 ± 41.5

118.8 ± 47.8

115.5 ± 38.9

0.923^a

HbA1c (%)

6.12 ± 0.94

5.98 ± 0.80

5.82 ± 0.60

0.173^a

Glucose-lowering medication

8 (16.7%)

8 (16.7%)

8(16.7%)

1.000^b

LDL-cholesterol (mg/dl)

114.2 ± 24.0

118.0 ± 28.2

124.6 ± 25.5

0.146^a

Lipid-lowering medication

13 (27.1%)

16 (33.3%)

17 (35.4%)

0.660^b

Uric acid (mg/dL)

5.50 ± 1.26

5.25 ± 1.29

5.38 ± 1.32

0.643^a

Body mass index (kg/m²)

24.13 ± 3.87

24.03 ± 3.20

24.19 ± 3.56

0.977^a

eGFR (ml/min/1.73 m²)

68.0 ± 19.4

67.5 ± 15.9

64.9 ± 17.8

0.667^a

Proteinuria

4 (8.3%)

6 (12.5%)

7 (14.6%)

0.627^b

Cardiovascular disease

9 (18.8%)

8 (16.7%)

7 (14.6%)

0.861^b